With its experimental psoriasis drug stymied for undisclosed reasons and the rest of its pipeline failing to live up to expectations, Abbott Labs today announced plans to cut 1,900 workers, or some six percent of its workforce, from its commercial and manufacturing divisions. Abbott's recent R&D flops include the cholesterol drug Certriad. And without the extra cash from newly approved drugs flowing in, workers have to flow out. Story